Genes and primary headaches: discovering new potential therapeutic targets by Rainero, Innocenzo et al.
Rainero et al. The Journal of Headache and Pain 2013, 14:61
http://www.thejournalofheadacheandpain.com/content/14/1/61REVIEW ARTICLE Open AccessGenes and primary headaches: discovering new
potential therapeutic targets
Innocenzo Rainero1*, Elisa Rubino1, Koen Paemeleire2, Annalisa Gai1, Alessandro Vacca1, Paola De Martino1,
Salvatore Gentile1, Paola Sarchielli3 and Lorenzo Pinessi1Abstract
Genetic studies have clearly shown that primary headaches (migraine, tension-type headache and cluster headache)
are multifactorial disorders characterized by a complex interaction between different genes and environmental
factors. Genetic association studies have highlighted a potential role in the etiopathogenesis of these disorders for
several genes related to vascular, neuronal and neuroendocrine functions. A potential role as a therapeutic target is
now emerging for some of these genes. The main purpose of this review is to describe new advances in our
knowledge regarding the role of MTHFR, KCNK18, TRPV1, TRPV3 and HCRTR genes in primary headache disorders.
Involvement of these genes in primary headaches, as well as their potential role in the therapy of these disorders,
will be discussed.
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Primary headache disorders, according to the Inter-
national Classification of Headache Disorders 2nd edition
(ICHD-II), include migraine, tension-type headache, clus-
ter headache, and other primary headaches [1]. Primary
headaches represent a common and major health problem
worldwide and significantly impair patients’ quality of life
[2,3]. These disorders may affect individuals from child-
hood and are most troublesome in the productive years
of life, thus generating an economic burden for both
society and healthcare systems [4,5]. Recently, Global
Burden of Disease (GBD) studies have rated primary
headaches among the top ten disorders causing sig-
nificant disability [6].
In recent years, genetic studies have provided sub-
stantial evidence supporting the notion that primary
headaches are complex, multifactorial disorders. Popula-
tion, family and twin studies have shown that migraine,
tension-type headache and cluster headache have a sig-
nificant heritable component [7,8]. Different genetic fac-
tors may, therefore, be involved in the generation of a
specific “headache threshold”. In rare primary headache* Correspondence: innocenzo.rainero@unito.it
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in any medium, provided the original work is psubtypes, such as Familial Hemiplegic Migraine (FHM),
single gene mutations co-segregate with disease pheno-
type [9-11]. In the more common forms of primary
headaches, as in other complex diseases, the phenotype
is thought to be caused by an interaction of multiple
genetic variants, each of them having a small to medium
effect, with different environmental factors.
Due to the complexity of these disorders, the isola-
tion of different genetic factors involved in primary
headaches has proven to be difficult. Genetic association
studies have provided evidence that genes involved in
vascular, neuronal and endocrine functions may have a
significant role in primary headaches [12,13]. The pur-
pose of this review is to highlight recent discoveries, in
particular about methylenetetrahydrofolate reductase
(MTHFR), potassium channel, subfamily K member 18
(KCNK18), transient related potential vanilloid type 1
(TRPV1), transient related potential vanilloid type 3
(TRPV3), hypocretin (orexin) receptor 1 (HCRTR1) and
hypocretin (orexin) receptor 2 (HCRTR2) genes which
are involved in different subtypes of primary headaches
and that, in the near future, might be of relevance as
novel therapeutic targets.an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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In the last two decades, molecular genetic studies pro-
vided substantial evidence concerning the potential role
of multiple genes in primary headaches. The majority of
these studies evaluated genetic factors involved in mi-
graine, while molecular genetics of cluster headache and
tension-type headache has been little studied, so far.
Vascular genes and primary headaches
Migraine and cluster headache have long been consid-
ered vascular disorders. Even if the so-called “vascular
theory” of migraine has been shown to be inadequate in
explaining the complex symptoms of the disorder, both
migraineurs and cluster headache patients show ab-
normalities in both cranial and extracranial vascular
reactivity [14,15]. In addition, both disorders are cha-
racterized by a significant comorbidity with diseases
such as stroke, myocardial infarction, hypertension and
Raynaud’s phenomenon [16-18]. Several genes involved
in vascular functions, such as endothelin-1 (ETA-1),
angiotensin-converting enzyme (ACE), Neurogenic Locus
Notch Homolog Protein 4 (NOTCH4) and methylenete-
trahydrofolate reductase (MTHFR) genes have been stud-
ied in patients with primary headaches and some of these,
such as the MTHFR gene, were significantly associated
with migraine [19-24].
The MTHFR gene is located on chromosome 1p36.3; it
consists of 11 exons and encodes for the methyle-
netetrahydrofolate reductase, a crucial enzyme involved in
purine and thymidylate biosynthesis, methylation of
DNA and amino acids, and neurotransmitters synthesis.
The MTHFR enzyme catalyzes the reduction of 5, 10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate, a
substrate needed for the conversion of homocysteine to
methionine (Figure 1). This pathway is folate-dependentGlutath
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MSR = methionine-synthase-reductase.and a lack of dietary folate can produce an increase in
homocysteine levels. The clinical consequences of in-
creased homocysteine plasma concentrations include
endothelial cells injury and alterations in coagulant prop-
erties of blood [25-27]. Furthermore, homocysteine de-
rivatives act as NMDA receptor agonists and they may
enhance glutamatergic neurotransmission, thereby increa-
sing the spontaneous trigeminal cells firing and predispo-
sing cortical neurons to hyperexcitability [28,29].
Several genetic variants have been described in the
MTHFR gene. Genetic research investigating the role of
MTHFR in primary headaches has focused almost ex-
clusively on two common polymorphisms, due to their
functional activity. These are a cytosine (C) > thymine
(T) change at position 677 in exon 4, that results in
a substitution of an alanine into a valine amino acid
(Ala222Val) in the catalytic domain, and an adenine
(A) > cytosine (C) change occurring at position 1298 in
exon 8, that changes a glutamate into an alanine amino
acid (Glu429Ala). The C677T genetic variant allele
produces a 35% reduction of MTHFR enzyme activity
whereas the A1298C variant results in decreased MTHFR
activity to a somewhat lesser degree [30]. These two vari-
ants have been extensively associated with the pathogen-
esis of several disorders, such as cardiovascular disease,
cerebrovascular disease, and psychiatric disorders [31-35].
A large number of studies also provided evidence of
an association between migraine and the C677T poly-
morphism in the MTHFR gene [22-24]. This association
seems significant mainly in patients affected by migraine
with aura (MA) while in patients affected by migraine
without aura (MO) the results are conflicting. Two re-
cent genetic meta-analysis provided clear evidence of a
significant association between MA and the MTHFR
gene: the carriage of the T allele was shown to beione 
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risk [36,37].
More recently, in Norfolk Island Population, three
MTHFR single nucleotide polymorphisms (SNPs) were
associated with migraine. These three SNPs are located
in intron 7 (rs6696752), in the 3′ untranslated region
(rs4846048), and in exon 11 (rs2274976, non synonym-
ous, producing a substitution of arginine to glutamine,
R594Q) and have not previously been reported to show
any genetic association with migraine. These findings
reinforced the potential role of MTHFR in migraine sus-
ceptibility [37].
A recent case–control study examined the association
between MTHFR polymorphisms and cluster headache
in a group of 147 cases and 599 Caucasians controls.
This study found no evidence of association between
genotypes of the MTHFR 677C>T polymorphism and
cluster headache overall. However, subgroup analyses
suggested that carriers of the MTHFR 677 T allele may
have an increased risk for chronic cluster headache,
suggesting a need for additional studies in order to
evaluate a possible role of MHTFR as modifier gene
in the disorder [38]. At present, no study examined
the potential association between tension-type head-
ache and MTHFR polymorphisms.
Hyperomocysteinemia has been reported in patients
with migraine [39]. Folic acid, vitamin B6 and vitamin
B12 supplementation has been found to be effective in
reducing the occurrence of migraine attacks [40]. There-
fore, a recent pharmacogenetic study evaluated the
effects of different MTHFR and 5-methyltetrahydrofolate-
homocysteine methyltransferase reductase (MTRR) geno-
types on the occurrence of migraine in a double-blinded
placebo-controlled trial of daily vitamin B supplementa-
tion. Patients carrying the C allele of the MTHFR C677T
variant showed a higher reduction in homocysteine levels,
severity of pain and migraine disability, when compared
with those with the T allele. MTRR catalyzes the reme-
thylation of homocysteine to methionine, and, similarly,
the A allele carriers of theMTRR A66G variants showed a
higher degree of reduction in homocysteine levels, severity
of pain and percentage of severe migraine disability, when
compared with those carrying the GG genotypes [41].
This pivotal study suggests that both MTHFR and MTRR
gene variants may influence the response to treatment
with vitamin B in migraineurs. Conversely, genetic data
concerning the role of vascular genes in tension-type
headache are still scarce. A recent meta-analysis investi-
gated the genetic role of the endothelin type A receptor
(EDNRA) – one of the two receptors of the potent vaso-
constrictor ETA-1 – in migraineurs and in patients with
tension-type headache [42]. This meta-analysis included
440 migraineurs, 222 patients with tension-type headaches
and 1323 controls from three previous studies reportingconflicting results about EDNRA -231G>A polymorphism.
It found a significant difference in the frequency of AA
genotype between migraine subjects and healthy controls.
However, no differences were found in the distribution of
the EDNRA -231G>A SNP between patients with tension-
type headaches and controls.Neuronal genes and primary headaches
Several clinical and experimental data support the con-
cept of abnormal cortical excitability as the pivotal phy-
siological disturbance in migraine [43,44]. Mutations in
genes that code for ion channels or pumps (CACNA1A,
ATP1A2, and SCN1A) have been described in FHM,
strongly supporting the hypothesis that migraine may
be classified as a “cerebral ionopathy” [45]. CaV 2.1
(CACNA1A) calcium channels are located in the pre-
synaptic terminal of both excitatory and inhibitory neu-
rons, NaV 1.1 (SCN1A) sodium channels are expressed in
inhibitory interneurons while Na+/K+ATPase (ATP1A2) is
located at the surface of glial cells (astrocytes). Knock-in
mouse models carrying such mutations showed an in-
creased susceptibility to cortical spreading depression, the
likely underlying mechanism of migraine aura [46,47].
Finally, an interesting comorbidity between migraine and
epilepsy has been described, further supporting a role
for ion homeostasis genes in migraine pathophysiology
[48,49]. However, until few years ago, no ion channel gene
involvement has been described in the common form of
migraine or in other primary headaches disorders.
In 2010, a frameshift mutation in the KCNK18 gene
which segregates perfectly with typical MA in a large,
multigenerational pedigree was reported [50]. This gene
codes for TWIK-related spinal cord potassium channel
(TRESK), a member of the two-pore domain (K2P) po-
tassium channel family. Functional characterization of
the F139WfsX24 mutation demonstrated that it cau-
ses a complete loss of TRESK function and that the
mutant subunit suppresses the wild-type channel function
through a dominant-negative effect.
The KCNK18 gene is located on chromosome 10; it
encodes a protein containing 4 transmembrane domains
(TMDs), and two pore-forming domains. The extracellu-
lar domain located between TMD1 and TMD2 contains
a conserved cysteine residue that may form a disulfide
bridge to aid channel dimerization, and a conserved
N-linked glycosylation site, important for surface expres-
sion of the channel [51]. In humans, the family of KP2
channels includes 15 related channels but TRESK is
unique in having a large intracellular regulatory domain
located between TMD2 and TMD3. TRESK is abun-
dantly expressed in the dorsal root ganglion (DRG), and
in other sensory ganglia such as the trigeminal gang-
lion (TG). TRESK was also found in human autonomic
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paravertebral sympathetic chain [50,52].
The TRESK is an outwardly rectifying K+ current
channel that contributes to the resting potential and is
the most important background potassium channel in
DRG. TRESK is activated in a complex manner by intra-
cellular calcium signalling. The calcium/calmodulin-
dependent protein phosphatase, calcineurin, activates
TRESK function [53,54]. Calcineurin also regulates nu-
clear factor of activated T cells (NFATs), transcription
factors that regulate inducible expression of many cyto-
kines. In addition, recent studies have identified volatile
anesthetics as highly potent TRESK agonists, interacting
directly with the channel. On the contrary, cyclosporin
A and tacrolimus, two potent immunosuppressants that
specifically inhibit the calcineurin activation of NFATs,
mimic a TRESK loss of function by keeping the channel
insensitive to increases in intracellular Ca2+.
The physiological functions of TRESK have been
mainly investigated in knock-out (KO) mice. The KO
mice show no gross anatomical or behavioral phenotype.
The gene ablation has minimal effect on the resting mem-
brane potential. However, DRG neurons from TRESK KO
mice displayed a lower threshold for activation, reduced
action potential duration, and slightly higher amplitudes
of after-hyperpolarization, suggesting that DRG neurons
from KO mice were more excitable than wild-type DRG
neurons [55]. In addition, due to the coupling of TRESK
to the histamine H1 receptor, the channel may reduce
neuronal excitability in inflammatory conditions when his-
tamine or other inflammatory modulators are released
into the surrounding tissue. Taken together, these data
suggest an important role of TRESK in both acute and
chronic pain conditions [56].
After the identification of KCNK18 gene mutation in a
Canadian MA pedigree, a large cohort of unrelated MA
patients and healthy controls was screened for gene mu-
tation. Several missense variants (R10G, A34V, C110R,
S231P and A233V) were found. These variants either
had no apparent functional effect, or they caused a re-
duction in channel activity. The A34V was identified in
a single Australian migraine proband for which family
samples were not available, but it was not detected in
controls. By contrast, the R10G, C110R, and S231P vari-
ants were found in both migraineurs and controls. The
authors concluded that the presence of a single non-
functional variant in the KCNC18 gene is probably not
sufficient to determine whether an individual develops
migraine [57].
In a recent study, we examined the presence of
KCNK18 gene mutations in a large data set of Italian mi-
graine patients (both with MA and MO) and healthy
controls. We confirmed the presence of KCNK18 gene
mutations in MA and also found gene mutations in MOpatients [58]. Some of these gene variants have not previ-
ously been described. However, the functional relevance of
these mutations still need further investigations. Finally,
KCNK18 gene involvement in tension-type headache or
cluster headache has not been investigated yet.
The TRESK K2P channel is a novel and interesting
component of the migraine pathogenesis pathway and
represents an excellent opportunity for development of
antimigraine therapy, given its highly selective expres-
sion pattern in neuronal structures, which is known to
be important in disease pathogenesis. Its highly specific
expression pattern in TG, DRG and parasympathetic
neurons and the presumed role in abating neuronal
excitability under inflammatory conditions make it an
excellent target for development of new migraine
therapeutics [59,60]. Specific agonists could upregu-
late TRESK activity and may have a potential in both
acute and preventive migraine therapy, as well as in
other pain disorders.
Recently, the transient receptor potential (TRP) chan-
nels gained increased interest for their potential involve-
ment in primary headaches [61,62]. There are at least 30
members of the mammalian TRP family, which are
coded by several, different genes. TRP channels are dis-
tributed in many peripheral tissues as well as central and
peripheral nervous system. Several TRP family mem-
bers, including the TRPV1 (Transient Related Potential
Vanilloid Type 1), TRPV2 (Transient Related Potential
Vanilloid Type 2), TRPV3 (Transient Related Potential
Vanilloid Type 3) and TRPV4 (Transient Related Poten-
tial Vanilloid Type 4), TRPM8 (Transient Related Poten-
tial Metastatin Type 8) channels, are polymodal sensors
expressed in the sensory neurons of dorsal root ganglia
(DRG) and trigeminal ganglia (TG) [63]. In particular,
TRPV1 receptor is highly co-expressed with calcitonin-
gene related peptide (CGRP) a potent vasodilator with
an important role in migraine. TRPV1 is also co-
expressed with other pain signalling molecules such as
substance P, P2X3 purinergic receptors and other mar-
kers of nociceptive C and Aδ fibers [64]. It has been pro-
posed to play a crucial role as mediators of neuropathic
pain and have been proposed to play a role in migrai-
neous allodynia and sensitization phenomena [65].
Using a genetic association strategy, in 2012 Carreno
et al. found a significant association between SNPs with-
in the TRPV1 and TRPV3 genes and migraine in the
Spanish population [66]. Interestingly, TRPV1 and TRPV3
are located in close proximity on the 17p13 chromosomal
region and they share a high sequence homology. In the
meanwhile, two genome-wide association studies (GWAS)
found evidence of a significant association between ge-
netic markers in or near the TRPM8 gene and migraine
[67,68]. TRPM8 gene is expressed by a different TRPV1-
negative neuronal subpopulation in DRG and TG. These
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nels in the pathogenesis of primary headaches.
TRP channels have been among the most aggressively
pursued drug targets over the past few years and several
studies suggested these channels as potential therapeutic
targets in migraine. Both peripheral and central nerve
terminals at the spinal cord can be targeted to induce
pain relief by TRPV1 agonists. In particular, the anal-
gesic effects of the TRPV1 antagonist SB-705498 on
trigeminovascular sensitization and neurotransmission
have been studied in an animal model of neurovas-
cular head pain [69,70]. Recently, a phase II clinical
trial using SB-705498 has been conducted for the
acute treatment of migraine attacks but results are
pending (ClinicalTrials.gov).
Neuroendocrine genes and primary headaches
A large number of endocrine abnormalities has been de-
scribed in patients with primary headaches [71,72]. The
hypothalamus, with its paramount control of the endo-
crine system, as well as its widespread connections with
both central and autonomic nervous system, exerts a
pivotal role in the pathogenesis of both migraine and
cluster headache [73]. Therefore, genes that code for
proteins involved in endocrine functions are candidate
genes for primary headache disorders. Polymorphisms in
genes that code for estrogen and progesterone receptors
have been intensively studied in migraineurs, with con-
trasting results [74,75].
In 1998, two research groups independently discovered
a new hypothalamic peptidergic system. The former
group named the peptides “hypocretins”, because of
their hypothalamic location and structural similarity to
the incretin family of hormones [76]. The latter group
named the peptides “orexins”, due to the appetite-
enhancing properties when administered centrally to
rats [77].
Subsequent studies revealed complex and interesting
neurobiological effects of these peptides, with particular
relevance to the pathophysiology of primary headaches
[78].
The hypocretins (Hcrt-1 and Hcrt-2), also called
orexins, are peptides derived by proteolytic cleavage
from the same 130 amino acid precursor peptide
(prepro-hypocretin). A single gene located on chromo-
some 17q21 in humans is responsible for encoding
prepro-hypocretin. The human prepro-hypocretin gene
consists of 2 exons and 1 intron. The hypocretins bind to
2 G-protein coupled receptors, termed HCRTR1 and
HCRTR2. The HCRTR1 gene in humans is located on
chromosome1p33 whereas the HCRTR2 gene is located
on chromosome 6p11. Both genes consist of 7 exons and
6 introns. Hcrt-1 has equal affinity for both HCRTR1 and
HCRTR2, with Hcrt-2 demonstrating a 10-fold higheraffinity for HCRTR2 than HCRTR1. Activation of both re-
ceptors results in elevated levels of the intracellular Ca2+
concentrations, and this in turn results in the enhance-
ment of the Gq-mediated stimulation of phospholipase C.
Hypocretin immunoreactive cell bodies have been ob-
served mainly in the hypothalamus [79]. Hypocretin-
containing neurons have widespread projections through-
out the CNS with particularly dense excitatory projections
to monoaminergic and serotonergic brainstem centers
[80]. The hypocretin system influences a wide range of
physiological processes in mammals, such as feeding,
arousal, rewards, and drug addiction [81,82]. Recently, a
number of studies in experimental animals showed that
hypocretins are involved in pain modulation within the
CNS, and suggested an important role for these peptides
in primary headaches [83].
In 2004, our research group investigated the possible
involvement of the hypocretin transmission in cluster
headache. We selected several DNA polymorphisms of
the three genes that constitute the hypocretin system
and, using a case–control strategy, we evaluated possible
allelic and genotypic differences in a group of 109 CH
patients and 211 controls. Genetic analysis revealed that
both allelic and genotypic frequencies of the G1246A
polymorphism in the HCRTR2 gene were significantly
different between CH patients and controls [84]. Sub-
jects homozygous for the G allele, in comparison with
the remaining genotypes, were 5-fold more likely to de-
velop the disease. This association was confirmed in a
large group of CH patients and controls from Germany
[85]. On the contrary, Baumber et al. found no associ-
ation between CH and the HCRTR2 gene in a cohort of
259 patients of Danish, Swedish, and British origin [86].
To resolve this issue, we performed a genetic meta-
analysis of the previous studies (593 cases and 599 con-
trols) and a haplotype analysis: both these studies con-
firmed the presence of a significant association between
the HCRTR2 gene and CH [87]. At present, the possi-
ble involvement of the hypocretin system in migraine
has been scarcely investigated. Studies in CH patients
prompted two independent research groups to evaluate
the association of the G1246A polymorphisms in the
HCRTR2 gene with migraine. Both studies found no as-
sociation between this polymorphism and migraine or
its clinical subtypes [88,89]. Recently, we performed a
genetic case–control study to investigate whether gen-
etic variants in the HCRTR1 gene could modify the oc-
currence and the clinical features of migraine. Using a
case–control strategy we genotyped 384 migraine pa-
tients and 259 controls for three SNPs in the HCRTR1
gene. Genotypic and allelic frequencies of the rs2271933
non-synonymous polymorphism were different between
migraineurs and controls [90]. The carriage of the A al-
lele was associated with an increased migraine risk. This
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could represent a genetic susceptibility factor for mi-
graine and suggests that the hypocretin system may have
a role also in the pathophysiology of migraine. Unfortu-
nately, no data regarding involvement of HCRTR genes
in tension-type headache are currently available.
The growing knowledge concerning the role of hypo-
cretins/orexins in different neurological conditions has
generated considerable interest in developing small-
molecule hypocretin receptor antagonists as a novel
therapeutic strategy. Hypocretin antagonists, especially
those that block Hcrtr1 or both Hcrtr1 and Hcrtr2 re-
ceptors, have been studied mainly as new drugs for sleep
disorders. In experimental animals hypocretin/orexin an-
tagonists (almorexant, suvorexant) clearly promote sleep,
and clinical results are encouraging [91-94]. Considering
the high frequency of sleep disorders occurring in pa-
tients with migraine and CH, these drugs offer a new
perspective in the treatment of these disorders. Finally, a
pivotal role for these peptides in drug reward and drug
seeking has been established and their potential role as
anti-relapse medication in drug addiction is currently
under investigation in experimental animals [95].Conclusions
The main goal of genetic studies is to unravel molecular
pathways underlying primary headache disorders, in
order to discover new therapeutic targets. Recent studies
have highlighted a potential role for new genes, like
MTHFR, KCNK18, TRPV1, TRPV3, and new neurotrans-
mission systems, like the hypocretin system, both in mi-
graine and cluster headache. Additional experimental
and clinical studies are needed to better elucidate the in-
volvement of these new genes in primary headaches and
to evaluate new therapeutic strategies.
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